Home Cart Sign in  
Chemical Structure| 1818339-66-0 Chemical Structure| 1818339-66-0

Structure of PF-06751979
CAS No.: 1818339-66-0

Chemical Structure| 1818339-66-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PF-06751979 is a potent, brain penetrant, β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 7.3 nM in BACE1 binding assay.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PF-06751979

CAS No. :1818339-66-0
Formula : C18H19F2N5O3S2
M.W : 455.50
SMILES Code : O=C(C1=NC=C(OC(F)F)C=C1)NC2=CSC([C@@]34N=C(N)SC[C@]3([H])C[C@H](C)OC4)=N2
MDL No. :MFCD31657420

Safety of PF-06751979

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02793232 Healthy Subjects Phase 1 Completed - Belgium ... More >> Pfizer Clinical Research Unit Brussels, Belgium, B-1070 Less <<
NCT02793232 - Completed - -
NCT02509117 Healthy Subjects Phase 1 Completed - United States, California ... More >> California Clinical Trials Medical Group, Inc Glendale, California, United States, 91206 Glendale Adventist Medical Center Glendale, California, United States, 91206 Less <<
NCT02509117 - Completed - -
NCT03126721 Healthy Phase 1 Completed - Belgium ... More >> Pfizer Clinical Research Unit Brussels, Belgium, B-1070 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.20mL

0.44mL

0.22mL

10.98mL

2.20mL

1.10mL

21.95mL

4.39mL

2.20mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories